home / stock / artl / artl news

ARTL News and Press, Artelo Biosciences Inc. From 03/25/24

Stock Information
Company Name: Artelo Biosciences Inc.
Stock Symbol: ARTL
Market: OTC
Website: artelobio.com
Menu
ARTL ARTL Quote ARTL Short ARTL News ARTL Articles ARTL Message Board
Get ARTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ARTL - Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condi...
ARTL - Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today ...

ARTL - Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it w...

ARTL - Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today a...
ARTL - Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today a...

ARTL - Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced ...

ARTL - Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced ...
ARTL - Expected earnings - Artelo Biosciences Inc.

Artelo Biosciences Inc. (ARTL) is expected to report $-0.7 for Q3 2023

ARTL - Artelo Biosciences GAAP EPS of -$0.83 misses by $0.18

2023-11-13 14:40:04 ET More on Artelo Biosciences Seeking Alpha’s Quant Rating on Artelo Biosciences Historical earnings data for Artelo Biosciences Financial information for Artelo Biosciences For further details see: Artelo Biosciences GAAP EPS o...

ARTL - Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

$12.9 Million in Cash and Investments as of September 30, 2023; Runway Expected to Reach Meaningful Development Milestones On Track to Submit IND Application with the FDA for ART26.12 During the First Half of 2024 SOLANA BEACH, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Artel...
Previous 10 Next 10